Harpoon Therapeutics   Report issue

For profit Phase 1 Phase 2
Founded: South San Francisco CA United States (2015)

Organization Overview

First Clinical Trial
2018
NCT03577028
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Harpoon Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (3)

hpn217 (1 trial)

hpn328 (1 trial)

hpn536 (1 trial)

Drugs in Phase 1 Trials (1)

hpn424 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Neoplasms (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Prostatic Neoplasms (Phase 1)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4